Biogen

Innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.

Launch date

1978

Employees

Market cap

Enterprise valuation

AUD51.9b (Public information from Sep 2024)

Cambridge Massachusetts (HQ)

http://biogen.com

https://twitter.com/biogen https://www.facebook.com/biogen https://www.linkedin.com/company/biogen-

View job openings

Corporate Venture Fund: Biogen Idec New Ventures

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	13.4b	11.0b	10.2b	9.8b	9.6b	9.6b	9.8b
% growth	(6 %)	(18 %)	(7 %)	(3 %)	(2 %)	-	2 %
EBITDA	4.8b	3.7b	2.7b	2.6b	3.3b	3.5b	3.7b
% EBITDA margin	36 %	33 %	26 %	26 %	35 %	36 %	38 %
Profit	4.0b	1.6b	3.0b	1.2b	1.9b	2.2b	2.5b
% profit margin	30 %	14 %	30 %	12 %	20 %	23 %	25 %
EV / revenue	3.1x	3.4x	4.0x	4.4x	3.4x	3.2x	2.8x
EV / EBITDA	8.7x	10.3x	15.1x	16.7x	9.9x	8.8x	7.3x
R&D budget	4.0b	2.5b	2.2b	2.5b	-	-	-
R&D % of revenue	30 %	23 %	22 %	25 %	-	-	-

Date	Investors	Amount	Round
-	Nordic Biotech Asset Management Ventures Oxford University Innovation CRT Pioneer Fund International Biotechnology Trust	N/A	-
Sep 1991	N/A	N/A	IPO
Apr 2018	N/A	$2.1m	Grant
Total Funding		AUD3.2m

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 19 Switzerland 2 United Kingdom 2 Germany 1 South Korea 1

By Industry

By Round

ACQUISITION 8 SERIES A 5 SERIES B 4 LATE VC 2 SERIES C 2 EARLY VC 1 POST IPO EQUITY 1 GRANT 1 GROWTH EQUITY VC 1 NOT SET 1 SERIES D 1

Rodin Therapeutics

ACQUISITION by Alkermes Nov 2019

True North Therapeutics

ACQUISITION by Bioverativ May 2017

Neurimmune Holding

Resolvyx Pharmaceuticals

ACQUISITION by Biogen Feb 2014

ACQUISITION by LG Chem Oct 2022

ACQUISITION Dec 2011

Virdante Pharmaceuticals

ACQUISITION by Momenta Pharmaceuticals Dec 2011

Vivoryon Therapeutics

SAGE Therapeutics